qsai analysis and research center

Eurofins Strengthens Its Comprehensive Food Testing Offering in Japan Through the Acquisition of QSAI Analysis and Research Center Co.,Ltd.

LUXEMBOURG--( BUSINESS WIRE )--Regulatory News:

Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in food testing and a global scientific leader in bioanalytical testing, announces the signing of an agreement to acquire a majority stake in QSAI Analysis and Research Center Co.,Ltd. (“QARC”).

QARC was founded in 2013 as a spin-off from QSAI’s R&D center and has been consistently developing pesticide screening and other food testing capabilities for 20 years, serving an extensive customer base in the food, wholesale and retail industries as well as institutions and governments. QARC is recognised as one of the leading private pesticide testing laboratories in Japan, offering the largest portfolio of over 800 pesticide screening tests covering a variety of complex food matrices. QARC employs 80 people in its laboratories in Fukuoka and Nagoya and is accredited against ISO/IEC 17025 and The Ministry of Health, Labour and Welfare (MHLW).

The acquisition of QARC will complement the Eurofins network’s extensive food testing capabilities with pesticide, veterinary drug, foreign object and sensory testing services. The acquisition will further strengthen Eurofins’ presence in Japan and the Eurofins network’s offering to customers importing and exporting food products.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

For more information, please visit www.eurofins.com or contact: Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620 E-mail: [email protected]

• Group Menu ->

• Field Studies
• Ecotoxicology
• Regulatory Affairs
• Agro Testing
• Bioanalytical Services
• BioPharma Product Testing
• Contract Development & Manufacturing Organisation (CDMO)
• Pharma Discovery Services
• Pharma Early Development
• Pharma Central Laboratory
• Medical Device Testing
• Human Safety Testing
• Search Clinical Diagnostics
• Information
• Cosmetics & Personal Care
• Electrical & Electronics
• Water Testing
• Air Testing
• Soil Testing
• Building Materials
• Pollution Testing
• Waste Testing
• Fuel / Oil Testing
• Environment Laboratories
• Environmental Testing News
• Food Testing Services
• Food Testing Industries
• Food Testing Flyers
• Food Testing Laboratories
• Forensic DNA Analysis
• Forensic toxicology
• Quality and Safety
• Next Generation Sequencing
• Gene Synthesis & Molecular Biology
• Genotyping & Gene Expression
• DNA & RNA Oligonucleotides
• Custom DNA Sequencing
• News & Events
• In Vitro Diagnostics Solutions
• Maritime Services
• Materials and Engineering
• PSS Insourcing Solutions ®
• Testing Services
• News and useful links
• Sensory and Consumer Research
• Sustainability Services
• Eurofins Fact Sheet
• Eurofins Group overview
• Eurofins Strategy and Objectives
• Eurofins Entrepreneurship Model
• 30th Anniversary (2017)
• Our Vision, Mission and Values
• Leadership Charter
• Board of Directors
• Group Operating Council
• Eurofins Foundation
• CO2 Emissions
• ISO 14001 (Environmental Management)
• Spotlight: Examples of Local Environmental Initiatives
• Recruitment
• Training and Academy
• FT Diversity Leader by Financial Times
• OHSAS 18001 / ISO 45001 (Occupational Health and Safety)
• Total Recordable Incidence Rate (TRIR)
• Spotlight: Examples of Local Social Initiatives
• Code of Ethics and Values
• Eurofins Core Compliance Documents
• Whistleblowing
• Giving Back
• Carbon Neutrality - 2025 Objective
• Our Commitment to the UN Sustainable Development Goals
• Scientific Collaborations
• Your Career at Eurofins
• Our Global Locations
• COVID-19-Response
• Testing for Life
• A New Era of Oncological Data
• Fighting an Animal Health Endemic
• 20 Million Tests a Month to Help Protect the World Against COVID-19
• Protecting Crops and Human Health at the Same Time
• Ensuring Liquid Gold is the Real Deal
• Detecting a Silent Threat – Transplant Rejection
• What Do Pizza Boxes, Raincoats and Frying Pans Have in Common?
• Seeking Out a Silent Killer
• Protecting Cancer Patients
• Safeguarding the Health of the World’s Most Vulnerable Consumers – Infants
• Tackling the Big Problem of Tiny Particles
• Protecting Transplant Patients and Saving Lives
• Busting the Identical Twin Myth
• New Generation of Non-Invasive Prenatal Testing Methods
• SNIF-NMR - How it All Began
• The Future of Bees, the Future of Life
• Helping to stop Zika in its tracks
• A Pioneer in Dioxins Detection
• Acrylamide on the Tip of Everyone’s Tongue
• Fuelling the First Astronauts
• Testing for Traceability of Meat From Farm to Fork Down to Individual Animals
• The Forefathers of Pesticide Testing
• 30 Years of Data for Life
• Finding Adulteration Even When Not Looking for it
• Modern Farming is Precision Farming
• Beating Drug-Assisted Rape Forensically
• High-Flying Innovation
• Testing for Tailored Cancer Treatment
• Nurturing Cells to Grow
• Out of the Box Product Testing
• Inventing The Most Sensitive Heavy Metals Detection Method
• A Passive Revolution In Water Sampling
• Algae, Algae, Everywhere. Toxic and What a Stink
• Solving Old Crimes with New Technology
• Leading the World in GM Fish Detection
• Not Wanted Dead or Alive Mould and Bacteria
• Salmon under Threat – Detecting a New Contaminant of Concern
• Scientific Publications
• Shareholder Information
• Our Success in Numbers
• Audit and Risk Committee
• Sustainability and Corporate Governance Committee
• Nomination and Remuneration Committee
• Executives’ Dealings Disclosures
• Analyst Coverage
• Shares in Issue
• Corporate Timetable
• Bond Instruments
• Hybrid Capital Instruments
• Bond & Hybrid Capital Maturity Profile
• Commercial Paper Program
• Investor Relations Events Timetable
• Share buy-back programmes
• Press Releases
• Eurofins BioPharma Services Newsletter 34 - February 2023
• Eurofins BioPharma Services Newsletter 33 - October 2022
• Eurofins BioPharma Services Newsletter 32 - June 2022
• Eurofins BioPharma Services Newsletter 31 - February 2022
• Eurofins BioPharma Services Newsletter 30 - October 2021
• Eurofins BioPharma Services Newsletter 29 - June 2021
• Eurofins BioPharma Services Newsletter 28 - February 2021
• Eurofins BioPharma Services Newsletter 27 - October 2020
• Eurofins BioPharma Services Newsletter 26 - July 2020
• Eurofins BioPharma Services Newsletter 25 - February 2020
• Eurofins BioPharma Services Newsletter 24 - October 2019
• Eurofins BioPharma Services Newsletter 23 - June 2019
• Eurofins BioPharma Services Newsletter 22 - February 2019
• Group Directory PDF
• Czech Republic
• French Guiana
• Hong Kong (China)
• The Netherlands
• New Zealand
• Philippines
• Saudi Arabia
• South Africa
• Switzerland
• United Arab Emirates
• United Kingdom

Eurofins strengthens its comprehensive food testing offering in Japan through the acquisition of QSAI Analysis and Research Center Co.,Ltd.

Eurofins Scientific (EUFI.PA), the global leader in food testing and a global scientific leader in bioanalytical testing, announces the signing of an agreement to acquire a majority stake in QSAI Analysis and Research Center Co.,Ltd. (“QARC”).

QARC was founded in 2013 as a spin-off from QSAI’s R&D center and has been consistently developing pesticide screening and other food testing capabilities for 20 years, serving an extensive customer base in the food, wholesale and retail industries as well as institutions and governments. QARC is recognised as one of the leading private pesticide testing laboratories in Japan, offering the largest portfolio of over 800 pesticide screening tests covering a variety of complex food matrices. QARC employs 80 people in its laboratories in Fukuoka and Nagoya and is accredited against ISO/IEC 17025 and The Ministry of Health, Labour and Welfare (MHLW).

The acquisition of QARC will complement the Eurofins network’s extensive food testing capabilities with pesticide, veterinary drug, foreign object and sensory testing services. The acquisition will further strengthen Eurofins’ presence in Japan and the Eurofins network’s offering to customers importing and exporting food products. 

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

Investor Relations

Eurofins Scientific SE

Phone: +32 2 766 1620

E-mail: [email protected]

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or

Eurofins to acquire a majority stake in QSAI Analysis and Research Center

PARIS, FRANCE: Eurofins Scientific, the global leader in food testing and a global scientific leader in bioanalytical testing, announced the signing of an agreement to acquire a majority stake in QSAI Analysis and Research Center Co.,Ltd. (“QARC”).

QARC was founded in 2013 as a spin-off from QSAI’s R&D center and has been consistently developing pesticide screening and other food testing capabilities for 20 years, serving an extensive customer base in the food, wholesale and retail industries as well as institutions and governments.

QARC is recognised as one of the leading private pesticide testing laboratories in Japan, offering the largest portfolio of over 800 pesticide screening tests covering a variety of complex food matrices. QARC employs 80 people in its laboratories in Fukuoka and Nagoya and is accredited against ISO/IEC 17025 and The Ministry of Health, Labour and Welfare (MHLW).

The acquisition of QARC will complement the Eurofins network’s extensive food testing capabilities with pesticide, veterinary drug, foreign object and sensory testing services.

The acquisition will further strengthen Eurofins’ presence in Japan and the Eurofins network’s offering to customers importing and exporting food products.

  www.eurofins.com

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Save my name, email, and site URL in my browser for next time I post a comment.

• Search for: Search

Site Navigation

Listed Companies

• London Stock Exchange
• Singapore Exchange
• Canadian Exchange
• Australian Exchange
• Oslo Bourse
• Nasdaq Nordic
• Business & Finance
• Gadget Reviews
• About Us: Business News, Stock Market News, Financial News, Corporate Announcements

All news and articles on  NewsnReleases  are based on press releases, corporate announcements and analysts’ reports issued to  London Stock Exchange  (LSE), Euronext ,  Singapore Exchange (SGX) , Japan Stock Exchange (JPX),  Dubai Financial Market (DFM) , Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange  etc.

Equity Markets and Stock Exchanges

Eurofins strengthens its comprehensive food research in Japan with the acquisition of QSAI Analysis and Research Center Co. ,Ltd.

\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n

LUXEMBOURG, August 12, 2022–(BUSINESS WIRE)–Regulatory News:

Eurofins Scientific (EUFI. PA) (Paris:ERF), a global food leader and global clinical leader in bioanalyticalArray, announces the signing of an agreement to obtain a majority stake in QSAI Analysis and Research Center Co. ,Ltd. (“QARC”).

QARC founded in 2013 as a spin-off of centro R

The acquisition of QARC will complement the extensive food testing functions of the Eurofins network with testing facilities for pesticides, veterinary medicines, foreign bodies and sensors.

About Eurofins: the world leader in bioanalysis

Eurofins tests for life. Eurofins is the world leader in food, environmental, pharmaceutical and cosmetic testing, as well as contract study facilities in discovery pharmacology, forensics, complex tissue science and agroscience. Eurofins is also a market leader in safe testing and laboratory facilities for genomics, and in clinical study support, as well as in the progression and manufacture of BioPharma contracts. The Group also has an upcoming presence in molecular and highly specialized clinical diagnostic tests and in vitro diagnostic products.

With more than 61,000 employees in a decentralized, enterprise network of 940 laboratories in 59 countries, Eurofins delivers a portfolio of more than 200,000 analytical strategies to assess the safety, identity, composition, authenticity, origin, traceability and purity of a wide diversity of products, as well as the provision of state-of-the-art clinical diagnostic tests and in vitro diagnostic product services.

The Group’s goal is to provide its consumers with high-quality services, state-of-the-art responses and accurate effects in time. Eurofins preferentially ranks in the increasingly stringent criteria of quality and protection of its consumers and the growing demands of the regulatory government, as well as the needs of healthcare professionals around the world.

In 2020 and 2021, Eurofins reacted temporarily to address the global challenge of COVID-19, building the capacity to help more than 20 million patients each month who may have been affected by the pandemic with our testing products and facilities and directly supporting healthcare. professionals working on the front lines to fight the virus. The Group has established extensive PCR testing functions and conducted more than 40 million tests in its own laboratories, supports the progression of various vaccines, and implemented its testing, surveillance and consulting systems. ™ SAFER@WORK to help make certain environments, travel, and occasions safer COVID-19.

Eurofins has undergone a great expansion since its inception and its strategy is to continue expanding its generation portfolio and geographical reach. Thanks to the R

Eurofins Scientific shares are indexed on the Euronext Paris stock exchange (ISIN FR0014000MR3, Reuters EUFI. PA, Bloomberg ERF FP).

As long as it has not been lawfully made public through the distribution channels authorised by Eurofins, that document shall contain internal data within the meaning of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse. as amended.

Important Disclaimer:

This press release comprises forward-looking statements and estimates that involve hazards and uncertainties. The forward-looking statements and estimates contained herein constitute the judgment of Eurofins Scientific’s control as of the date of this press release. These forward-looking statements are not promises of long-term performance, and the prospective events discussed in this press release may not occur. Eurofins Scientific disclaims any legal purpose or liability to update those forward-looking statements and estimates. All statements and estimates are made on the basis of data to be under the control of the Company as of the date of publication, but their completeness or validity cannot be guaranteed.

See the businesswire. com edition: https://www. businesswire. com/news/home/20220811005031/en/

For more information, visit www. eurofins. com or contact: Investor RelationsEurofins Scientific SETéléphone: 32 2 766 1620E-mail: ir@eurofins. com

Leave a Comment Cancel Reply

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NVIDIA CORPORATION
• AMD (ADVANCED MICRO DEVICES)
• MICROSOFT CORPORATION
• SINGAPORE AIRLINES LIMITED
• NIPPON ACTIVE VALUE FUND PLC
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Quality stocks
• Dividend Aristocrats
• Growth stocks
• Undervalued stocks
• The Cannabis Industry
• The Internet of Things
• Biotechnology
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Cannibal companies
• The genomic revolution
• Europe's family businesses
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Eurofins Scientific SE

Fr0014000mr3, healthcare facilities & services.

• Eurofins Scientific SE signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Latest news about Eurofins Scientific SE

Chart eurofins scientific se.

Company Profile

Income statement evolution, analysis / opinion.

EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed

April 24, 2024 at 11:50 am EDT

Ratings for Eurofins Scientific SE

Analysts' consensus, eps revisions, quarterly revenue - rate of surprise, sector other healthcare facilities & services.

• Stock Market
• News Eurofins Scientific SE

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NVIDIA CORPORATION
• AMAZON.COM, INC.
• BOMBARDIER INC.
• THE EDINBURGH INVESTMENT TRUST PLC
• TESLA, INC.
• MICROSOFT CORPORATION
• Index Analysis
• Indexes News
• TSX VENTURE
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• United States
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Growth stocks
• Undervalued stocks
• Yield stocks
• Multibaggers
• Pricing Power
• Europe's family businesses
• Israeli innovation
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Biotechnology
• The food of tomorrow
• Gold and Silver
• The Internet of Things
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Eurofins Scientific SE

Fr0014000mr3, healthcare facilities & services.

• Eurofins Scientific SE signed of an agreement to acquire unknown majority stake in QSAI Analysis and Research Center Co., Ltd.

Latest news about Eurofins Scientific SE

Chart eurofins scientific se.

Company Profile

Income statement evolution, analysis / opinion.

EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed

April 24, 2024 at 11:50 am

Ratings for Eurofins Scientific SE

Analysts' consensus, eps revisions, quarterly revenue - rate of surprise, sector other healthcare facilities & services.

• Stock Market
• News Eurofins Scientific SE

残留農薬等の食品分析・食品検査ならユーロフィンQKEN

「ユーロフィンQKEN株式会社」に社名変更しました（旧社名：キューサイ分析研究所）

ユーロフィンQKENでは、残留農薬を中心とした食品分析・食品検査を行っています。

厚生労働省登録検査機関（厚生労働省発九厚1129第1号）（理化学的検査及び細菌学的検査の区分にて登録） ISO/IEC17025認定試験所（範囲限定）

Copyright © Eurofins QKEN K.K. All rights reserved.

Press release

Eurofins strengthens its comprehensive food testing offering in japan through the acquisition of qsai analysis and research center co.,ltd..

12 Aug 2022 07:15 CEST

Company Name

EUROFINS SCIENT.

FR0014000MR3

Regulatory News:

Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in food testing and a global scientific leader in bioanalytical testing, announces the signing of an agreement to acquire a majority stake in QSAI Analysis and Research Center Co.,Ltd. (“QARC”).

QARC was founded in 2013 as a spin-off from QSAI’s R&D center and has been consistently developing pesticide screening and other food testing capabilities for 20 years, serving an extensive customer base in the food, wholesale and retail industries as well as institutions and governments. QARC is recognised as one of the leading private pesticide testing laboratories in Japan, offering the largest portfolio of over 800 pesticide screening tests covering a variety of complex food matrices. QARC employs 80 people in its laboratories in Fukuoka and Nagoya and is accredited against ISO/IEC 17025 and The Ministry of Health, Labour and Welfare (MHLW).

The acquisition of QARC will complement the Eurofins network’s extensive food testing capabilities with pesticide, veterinary drug, foreign object and sensory testing services. The acquisition will further strengthen Eurofins’ presence in Japan and the Eurofins network’s offering to customers importing and exporting food products.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005031/en/

For more information, please visit www.eurofins.com or contact: Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620 E-mail: [email protected]

EUROFINS INTERNATIONAL SUPPORT SERVICES LUX SARL

BusinessWire

• AEX index Stocks
• AEX ESG Stocks
• Structured products
• Index options
• Index futures
• Stock options
• Dividend derivatives
• Stock futures
• Quote Vendor Codes
• Euronext regulated
• Euronext Growth
• Euronext Access
• Expert Market
• BEL 20 Stocks
• Structured Products
• ISEQ 20 Stocks
• Irish Government Bonds
• Euronext Milan
• Euronext Growth Milan
• Euronext Star Milan
• Euronext Global Equity Market
• Trading After Hours
• MIB ESG Stocks
• Euronext Access Milan
• All derivatives
• Euronext Expand
• Top performers
• OBX ESG Stocks
• OSEBX stocks
• OSEFX Stocks
• Seafood Stocks
• Shipping Stocks
• Equity indices
• Nordic Alternative Bond Market
• Bond indices
• Derivative products
• Financial calendars
• Primary insiders
• CAC 40 Stocks
• CAC 40 ESG Stocks
• All Markets
• Listing sponsors
• Euronext Tech Leaders
• Family business
• ESG indices
• Indices documents
• Indices news
• Index consultations
• Contact Euronext indices
• Oslo Mutual Funds
• Directory / search
• Bid-Only trading status
• Trading Turbos in the Netherlands
• Index Futures
• Index Options
• Stock Options
• Stock Futures
• Dividend Derivatives
• ETF Options
• Contracts specifications
• Wholesale Trading
• Quote vendor codes
• Quotes snapshot
• Milling Wheat futures
• Rapeseed futures
• Corn futures
• European Durum Wheat Futures
• Milling Wheat options
• Rapeseed options
• Corn options
• Trading calendars
• Commitments of Traders (CoT) report
• Bid & Ask
• Contract Specifications
• Position Management
• Intrinsic Value
• Premium & Valuation
• Euronext News
• Quality of execution
• Trading hours & Holidays
• Contract specifications
• Class level
• Product group level
• Cash Notices / Corporate actions
• All Corporate Actions
• Unusual Contract Sizes, Dividends
• Corporate Action Services
• Corporate Action Policies
• Derivatives notices
• Suspended instruments
• Stressed Market Conditions
• Breach of Double Cap limits
• Exceptional Market Conditions
• Miscellaneous short messages
• Market status
• Members list
• Issuers compliance
• Where to find

M&A Deal Summary

Eurofins scientific acquires qarc, on august 12, 2022, eurofins scientific acquired life science company qarc, acquisition highlights.

• This is Eurofins Scientific’s 69th transaction in the Life Science sector.
• This is Eurofins Scientific’s 4th transaction in Japan.

Search 193,804 Deals Now

• Buyer Type (PE or Strategic)
• Deal Size ($10M to $10B+)
• Sector (60 Sectors)

Try For Free 7-Day Free Trial

Eurofins Scientific

Description.

Eurofins Scientific is an international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. Eurofins Scientific was incorporated in 1987 and is based in Luxembourg City, Luxembourg.

PREVIOUS DEAL

Following deal.

• Mergr for Salesforce
• Mergr Data Direct
• Mergr M&A Archive

Eurofins Scientific Acquires QSAI Analysis And Research Center In Japan

EUROFINS STRENGTHENS ITS COMPREHENSIVE FOOD TESTING OFFERING IN JAPAN THROUGH THE ACQUISITION OF QSAI ANALYSIS AND RESEARCH CENTER CO.,LTD

We've detected unusual activity from your computer network

To continue, please click the box below to let us know you're not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy .

For inquiries related to this message please contact our support team and provide the reference ID below.